{"authors": [["Schepisi", "Giuseppe", "G", "Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. giuseppe.schepisi@irst.emr.it."], ["Farolfi", "Alberto", "A", "Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. alberto.farolfi@irst.emr.it."], ["Conteduca", "Vincenza", "V", "Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. vincenza.conteduca@irst.emr.it."], ["Martignano", "Filippo", "F", "Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. filippo.martignano@gmail.com."], ["De Lisi", "Delia", "D", "Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. d.delisi@unicampus.it."], ["Ravaglia", "Giorgia", "G", "Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. giorgia.ravaglia@irst.emr.it."], ["Rossi", "Lorena", "L", "Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. lorena.rossi@irst.emr.it."], ["Menna", "Cecilia", "C", "Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. cecilia.menna@irst.emr.it."], ["Bellia", "Salvatore Roberto", "SR", "Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. salvatore.bellia@irst.emr.it."], ["Barone", "Domenico", "D", "Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. domenico.barone@irst.emr.it."], ["Gunelli", "Roberta", "R", "Urology Unit, Forl\u00ec Hospital, Romagna Local Health Service, 47100 Forl\u00ec, Italy. r.gunelli@ausl.fo.it."], ["De Giorgi", "Ugo", "U", "Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. ugo.degiorgi@irst.emr.it."]], "date": "2017-12-05", "id": "29206214", "text": "Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.", "doi": "10.3390/ijms18122627", "title": "Immunotherapy for Prostate Cancer: Where We Are Headed.", "journal": ["International journal of molecular sciences", "Int J Mol Sci"]}